title: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
abstract: OBJECTIVE
  To test whether p34cdc2 overexpression, CD44s downregulation, and HER-2/neu amplification correlate with disease recurrence after radical prostatectomy, and to evaluate a possible biologic association between p34cdc2 and HER-2/neu expression.
  
  
  METHODS
  Immunohistochemical (IHC) detection of both p34cdc2 cyclin-dependent kinase (CDK) and CD44s expression and fluorescence in situ hybridization (FISH)-based analysis of HER-2/neu gene status were performed on formalin-fixed, paraffin-embedded sections of 106 prostatic adenocarcinomas (PACs). Findings were correlated with Gleason grade, pathologic stage, DNA ploidy, and postsurgical biochemical disease recurrence.
  
  
  RESULTS
  CDK overexpression correlated with tumor grade (P = .001), DNA ploidy (P = .001), pathologic stage (P = .04), and disease recurrence (P = .01). CD44s downregulation correlated with grade (P = .03), ploidy (P = .01), and recurrence (P = .02). HER-2/neu amplification correlated with grade (P = .001), ploidy (P = .001), and recurrence (P = .01). On multivariate analysis, CDK overexpression independently predicted recurrence (P = .001) after prostatectomy. CDK expression correlated with HER-2/neu status with 32 of 65 (49%) tumors that overexpressed CDK and showed concomitant HER-2/neu amplification (P = .04).
  
  
  CONCLUSIONS
  This study showed that p34cdc2, CD44s, and HER-2/neu are variably expressed or amplified in prostatic carcinoma and that such alteration may affect tumor behavior. In addition, CDK overexpression and HER-2/neu amplification may be biologically related.
authors.affiliation: Department of Pathology and Laboratory Medicine, Albany Medical College, NY, USA.
authors.forename: B V
authors.initials: BV
authors.lastname: Kallakury
authors.forename: C E
authors.initials: CE
authors.lastname: Sheehan
authors.forename: R A
authors.initials: RA
authors.lastname: Ambros
authors.forename: H A
authors.initials: HA
authors.lastname: Fisher
authors.forename: R P
authors.initials: RP
authors.lastname: Kaufman
authors.forename: P J
authors.initials: PJ
authors.lastname: Muraca
authors.forename: J S
authors.initials: JS
authors.lastname: Ross
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000235:genetics / Q000473:pathology* / Q000601:surgery*; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D015536:Down-Regulation; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D011003:Ploidies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology* / Q000601:surgery*
chemical_list: D018960:Hyaluronan Receptors; D018844:Cyclin-Dependent Kinases